We use cookies
BostonGene logo

De-risking oncology pipelines
through AI-driven multimodal analytics

BostonGene is a trusted industry partner

BostonGene’s platform combines deep biological insights with advanced AI and this collaboration will empower us to predict which patients will benefit from treatment helping us design safer, more effective therapies from the start. At AstraZeneca, we are focused on leveraging the vast and unparalleled potential of AI to accelerate clinical development and the delivery of innovative medicines to patients.
By embedding BostonGene’s AI-powered insights into our clinical framework, we are decoding the precise cellular and molecular pathways driving clinical outcomes. This clarity will allow us to move with greater speed and precision, ultimately strengthening the potential of IMGS-001 to address unmet medical needs for patients with cold or immune excluded tumors.

Accelerating every stage of drug development with simulational AI

From early target discovery to CLIA-certified companion diagnostics, BostonGene provides a biologically grounded roadmap to de-risk, validate, and advance your oncology pipeline.
Target identification
Mechanism of action and target status in different cells, tissues and diagnoses.
Biomarker discovery
Molecular signatures predicting therapy response and adverse events.
Drug repurposing
New drug indications based on target prevalence across different tissues and cancers.
Unmet need identification
Insights from systematic analysis of current treatment guidelines and recent clinical trials.
Clinical trial support
CLIA/CAP-certified solutions for patient profiling and response monitoring.

Transforming cancer care through AI innovation

An end-to-end AI platform for drug development
End-to-end AI drug development platform workflow diagram showing genomic and transcriptomic profiling stages End-to-end AI drug development platform workflow diagram showing genomic and transcriptomic profiling stages
Advanced technologies powered by AI-based analytics to drive breakthroughs in drug development
Whole exome sequencing
Unbiased detection of genetic variants across nearly 20,000 genes.
Whole transcriptome sequencing
Precise identification of gene fusions, gene expression levels and expression signatures.
Liquid Biopsy ctDNA, cfRNA
Minimally invasive tumor profiling from a standard blood sample.
scRNA-seq
High-resolution analysis of individual transcriptomes from thousands of cells within a single sample.
Flow cytometry
State-of-the-art flow cytometry solutions to assess immune system status from a standard blood sample.
Spatial proteomics
A comprehensive overview of tissue architecture and cell-cell interactions from a single slide.
Digital pathology
AI-based platform significantly reduces the need for manual analysis across various types of pathology data.
Whole exome sequencing
Unbiased detection of genetic variants across nearly 20,000 genes.
Whole transcriptome sequencing
Precise identification of gene fusions, gene expression levels and expression signatures.
Liquid Biopsy ctDNA, cfRNA
Minimally invasive tumor profiling from a standard blood sample.
scRNA-seq
High-resolution analysis of individual transcriptomes from thousands of cells within a single sample.
Flow cytometry
State-of-the-art flow cytometry solutions to assess immune system status from a standard blood sample.
Spatial proteomics
A comprehensive overview of tissue architecture and cell-cell interactions from a single slide.
Digital pathology
AI-based platform significantly reduces the need for manual analysis across various types of pathology data.
Helpful resources
Analytical and clinical capabilities Clinical research solutions Laboratory capabilities Solutions for patients stratification and research Kassandra™ BostonGene PAM50 Discovery solutions sample requirements Spatial proteomics